Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO
Details of the presentations are as follows:
Meeting: OIS@AAO
Session title: Company Showcase 2
Date:
Time:
Location:
Marriott Marquis Chicago
Presenter: Mark Iwicki,
Chairman and Chief Executive Officer of
Meeting: AAO
Title: KPI-121 0.25% for Short-term
Treatment of Dry Eye Disease: Results of a Multicenter Randomized Phase
3 Trial (STRIDE 1)
Date:
Time:
Location:
Presenter:
Meeting: AAO
Title: Phase 3 Results for KPI-121 1%
Ophthalmic Suspension Dosed BID Versus Placebo for the Treatment of
Ocular Inflammation and Pain Following Cataract Surgery
Date:
Time:
Location:
Presenter:
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFYTM mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. In preclinical studies, MPPs increased drug delivery into ocular tissues more than three-fold by facilitating penetration through the tear film mucus. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYSTM for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005260/en/
Source:
For Kala Pharmaceuticals, Inc.
Investors
Michael
Schaffzin, 212-362-1200
michael@sternir.com
or
Media
Kari
Watson, 781-235-3060
kwatson@macbiocom.com